BioSpace News Archive

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced the U.S. Food and Drug Administration has authorized the Company to proceed with a clinical trial of T-COVID, an investigational agent for the treatment of early COVID-19.

via NEWMEDIAWIRE – Progressive Care Inc.,a personalized healthcare services and technology company, is pleased to announce that the Company has selected Atlas Construction and Management LLC for the construction project at 400 Ansin Blvd in Hallandale Beach, FL.

OVAL independent Data Safety Monitoring Committee (DSMC) reviewed un-blinded data and determined that the study has met the interim pre-specified criterion of an absolute percentage advantage of 10% or higher in CA-125 response in the VB-111 treated arm compared to control. The DSMC recommended that the study proceed without modification.

Study to evaluate simultaneous blockade of PVRIG, TIGIT and PD-1 immune checkpoints Study to accelerate clinical evaluation of Compugen’s DNAM axis hypothesis and biomarker-driven approach in advanced solid tumors to broaden patient population responsive to cancer immunotherapy On-track to begin triple combination study during second half of 2020

Combined expertise in engineered exosomes and antigen prediction could drive a new approach to vaccine development - - engEx™ exosomes incorporating both B cell and T cell antigens plus adjuvants have potential to produce integrated immune response -

Vivet Therapeutics announced that both the Food and Drug Administration and the European Commission have granted Orphan Drug Designation for Vivet’s second gene therapy product, VTX-803, for the treatment of Progressive Familial Intrahepatic Cholestasis type 3.

ZEPOSIA is the first and only approved sphingosine-1-phosphate (S1P) receptor modulator with no genetic test or first dose observation at initiation

Zebra-Med’s AI1™platform is integrated in Apollo Radiology International’s dedicated COVID Reporting Center that reviews and analyzes all CT scans received across Apollo Hospitals around India.

Calliditas Therapeutics AB will launch an investor roadshow for a contemplated initial public offering of American Depositary Shares in the United States for trading on The Nasdaq Global Market in the United States and a concurrent private placement of common shares to certain qualified investors in Europe and other countries outside of the United States.

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced financial results for the three months ended March 31, 2020.